These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24844855)

  • 41. Key Recommendations from the MedtecHTA Project.
    Tarricone R; Torbica A; Drummond M;
    Health Econ; 2017 Feb; 26 Suppl 1():145-152. PubMed ID: 28139086
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Health Technology Assessment: managing the introduction and use of medical devices in clinical practice in Italy.
    Migliore A; Ratti M; Cerbo M; Jefferson T
    Expert Rev Med Devices; 2009 May; 6(3):251-7. PubMed ID: 19419283
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lean systems approaches to health technology assessment: a patient-focused alternative to cost-effectiveness analysis.
    Bridges JF
    Pharmacoeconomics; 2006 Dec; 24 Suppl 2():101-9. PubMed ID: 23389493
    [TBL] [Abstract][Full Text] [Related]  

  • 44. EVALUATION OF THE HTA CORE MODEL FOR NATIONAL HEALTH TECHNOLOGY ASSESSMENT REPORTS: COMPARATIVE STUDY AND EXPERIENCES FROM EUROPEAN COUNTRIES.
    Kõrge K; Berndt N; Hohmann J; Romano F; Hiligsmann M
    Int J Technol Assess Health Care; 2017 Jan; 33(6):644-653. PubMed ID: 29157316
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [HERA-QUEST: HTA evaluation of generic pharmaceutical products to improve quality, economic efficiency, patient safety and transparency in drug product changes in hospitals].
    Gyalrong-Steur M; Kellermann A; Bernard R; Berndt G; Bindemann M; Nusser-Rothermundt E; Amann S; Brakebusch M; Brüggmann J; Tydecks E; Müller M; Dörje F; Kochs E; Riedel R
    Z Evid Fortbild Qual Gesundhwes; 2017 Apr; 121():5-13. PubMed ID: 28545614
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies.
    Drummond M; Manca A; Sculpher M
    Int J Technol Assess Health Care; 2005; 21(2):165-71. PubMed ID: 15921055
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports.
    Taylor RS; Elston J
    Health Technol Assess; 2009 Jan; 13(8):iii, ix-xi, 1-50. PubMed ID: 19203465
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New technologies and surgical innovation: five years of a local health technology assessment program in a surgical department.
    Poulin P; Austen L; Kortbeek JB; Lafrenière R
    Surg Innov; 2012 Jun; 19(2):187-99. PubMed ID: 21949011
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Health technology assessment.
    Hailey D
    Singapore Med J; 2006 Mar; 47(3):187-92; quiz 193. PubMed ID: 16518551
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?
    Paulden M
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):239-242. PubMed ID: 28490259
    [No Abstract]   [Full Text] [Related]  

  • 51. The future of health technology assessment in healthcare decision making in Asia.
    Yang BM
    Pharmacoeconomics; 2009; 27(11):891-901. PubMed ID: 19888790
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical trial metadata: defining and extracting metadata on the design, conduct, results and costs of 125 randomised clinical trials funded by the National Institute for Health Research Health Technology Assessment programme.
    Raftery J; Young A; Stanton L; Milne R; Cook A; Turner D; Davidson P
    Health Technol Assess; 2015 Feb; 19(11):1-138. PubMed ID: 25671821
    [TBL] [Abstract][Full Text] [Related]  

  • 53. R You Still Using Excel? The Advantages of Modern Software Tools for Health Technology Assessment.
    Incerti D; Thom H; Baio G; Jansen JP
    Value Health; 2019 May; 22(5):575-579. PubMed ID: 31104737
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Are adverse effects incorporated in economic models? An initial review of current practice.
    Craig D; McDaid C; Fonseca T; Stock C; Duffy S; Woolacott N
    Health Technol Assess; 2009 Dec; 13(62):1-71, 97-181, iii. PubMed ID: 20018146
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Beyond clinical and cost-effectiveness: The contribution of qualitative research to health technology assessment.
    Germeni E; Szabo S
    Int J Technol Assess Health Care; 2023 Apr; 39(1):e23. PubMed ID: 37092753
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The value of value of information: best informing research design and prioritization using current methods.
    Eckermann S; Karnon J; Willan AR
    Pharmacoeconomics; 2010; 28(9):699-709. PubMed ID: 20629473
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union.
    Beletsi A; Koutrafouri V; Karampli E; Pavi E
    Value Health Reg Issues; 2018 Sep; 16():81-91. PubMed ID: 30316029
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Economic evaluation approaches for new technology.
    Papatheofanis FJ
    IEEE Eng Med Biol Mag; 2003; 22(3):16-7. PubMed ID: 12845811
    [No Abstract]   [Full Text] [Related]  

  • 59. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.
    Grimm SE; Strong M; Brennan A; Wailoo AJ
    Pharmacoeconomics; 2017 Dec; 35(12):1287-1296. PubMed ID: 28849538
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Technology assessment and the sociopolitics of health technologies.
    Lehoux P; Blume S
    J Health Polit Policy Law; 2000 Dec; 25(6):1083-120. PubMed ID: 11142053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.